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If you choose to resubmit, please include a cover letter addressing the reviewers' comments point by point. Please also highlight all changes in the text of the manuscript.
Regardless of how you choose to proceed, we hope that the comments below will prove constructive as your work progresses. We would be happy to discuss them further once you've had a chance to consider the points raised. You can contact the journal office with any questions, cellbio@rockefeller.edu or call (212) 327-8588.
Thank you for thinking of JCB as an appropriate place to publish your work. In this study, Sai et al provide evidence that RIPK3-MLKL signaling controls replication of the Grampositive bacterium Listeria monocytogenes in intestinal tissues and cells. Control of Listeria growth by RIPK3-MLKL signaling appears independent of necroptosis, and may instead rely on the direct bacricidal activity of unoligomerized MLKL. This study is timely as other host pore-forming proteins (such as Gasdermin D and granulysin) have very recently been shown to also possess direct antibacterial activity. Showing that MLKL may also function in this manner has important ramifications for the field. Nonetheless, further experimentation is needed to consolidate the findings and address unresolved issues. Major points: The most interesting aspect of this study is that MLKL may target and destroy Listeria independently of its capacity to trigger necroptosis. But these findings are currently underdeveloped and additional MLKL-centric experiments will be necessary. 1. Can the authors show that MLKL-deficient mice also fail to control Listeria spread to the liver? This is an essential experiment, given that RIPK3 may have MLKL-independent innate-immune functions in gut epithelium (e.g., Harris et al, Cell Host Microbe 18(2):221-32, 2015, a study that needs to be referenced in this paper) 2. How does MLKL limit Listeria without triggering cell death? Clues to mechanism here are provided by the NBB140 experiments shown in Fig 4, wherein the authors find that even unoligomerized MLKL can control Listeria. Given that oligomerization is unnecessary, does full-length MLKL also prevent Listeria growth in this setting? This is an important experiment, because if the full-length unphosphorylated protein can dampen bacterial growth, then the role of RIPK3 in this process becomes complicated. In other words, why phosphorylate MLKL? (Conventionally, phosphorylation of MLKL is thought of as a requisite for release of the NBB domain and membrane targeting.) If fulllength (unoligomerized) MLKL does not inhibit Listeria, but NBB140 (unoligomerized) MLKL does, then it would suggest that phosphorylation of MLKL by RIPK3 is needed to release the NBB domain, but that subsequent oligomirization of MLKL is unnecessary for targeting Listeria. Additional controls here would be to show that dimerized RIPK3 (using the same 2xFv system) also limits Listeria, but cannot do so when MLKL is absent (CRISPR) or RIPK3 activity is suppressed (RIPK3 inhibitor).
3. How does active (i.e., phosphorylated) MLKL in Listeria infected cells not trigger cell death, while similar amounts of active MLKL in TSQ-treated cells induce necroptosis? In a stepwise manner, the authors should evaluate compare MLKL status in Listeria versus TSQ-treated cells for (1) MLKL oligomerization (denuaturing gel), (2) MLKL plasma membrane trafficking (immunofluorescence using antibodies to MLKL and pMLKL, or following a Venus-or similarly tagged version of MLKL as shown by Quarato et al in Molecular Cell 61(4):589-601.) Relatedly, does Listeria infection of fulllength 2xFv MLKL or 2xFv-NBB140-expressing cells prevent cell death upon dimerization? That is, does Listeria actively prevent MLKL function/trafficking? This is not the same as showing effects on TSQ death by Listeria, as Listeria may inhibit TNF signaling independently of necroptosis. Also, is live Listeria required in the cytosol to trigger pMLKL? (Use of an LLO-mutant will help here.) 4. Listeria is a Gram-positive bacterium; its lipid membrane is therefore encased in a cell wall. How do the authors propose MLKL achieves access to the Listeria inner membrane? Can the authors extend their findings to Gram-negative bacteria, such as Salmonella sp. and E.coli? And is lipid binding by MLKL even important for its anti-Listeria activity (Quarato et al describe a mutant of MLKL without lipid binding capacity that will be useful here.) Of note, Gasdermin D is also effective against Gram-positive bacteria.
Minor points:
1. The following references (PMIDs supplied) need to be included: 26659062, 25577440, 23770239. These papers shown that Listeria can activate necroptosis/necrosis in other (non-intestinal) cell types. The Discussion should include a few sentences on why Listeria can activate necroptosis in some cell types and not others.
2. Referencing the Listeria 'plasma membrane' (page 11) omits the fact that the bacterium has a tough peptidoglycan cell wall surrounding its inner lipid membrane. The text in this page must be modified to reflect this fact.
Reviewer #2 (Comments to the Authors (Required)):
Sai and colleagues show that mice lacking the kinase RIPK3 show enhanced colonization of the liver by Listeria at 3 days after oral infection ( fig. 1e ). Unfortunately, the significance of this difference is unclear because they do not indicate the long-term consequences. For example, do RIPK3 KO mice exhibit more liver damage and increased mortality compared to wild-type littermates? Given that RIPK3 has roles outside of necroptosis signaling, it would also be useful to know if mice lacking the critical necroptosis effector MLKL are also more susceptible to Listeria infection.
In the remaining figures, the authors rely largely on HeLa cells reconstituted with exogenous RIPK3 to explore how RIPK3 might influence Listeria infection. They show that infection of HeLa cultures causes RIPK3-dependent MLKL phosphorylation and that this suppresses bacterial replication. However, unlike when Listeria infects macrophages and triggers RIPK3-dependent necroptosis 4. Fig. 4A -is MLKL phosphorylation required for colocalization with Listeria? i.e. Does RIPK3 deficiency or inhibition prevent co-localization? Quantitation of staining should be provided.
2
We agree that evaluating the involvement of MLKL in this protection pathway is important. We have successfully determined that Mlkl-deficiency reduced the ability of blocking Listeria spread to the liver (new Figure. 1F) . We note here that the bacterial burden in Mlkl-deficient mice liver is less than that in Ripk3-deficient mice, which implies that RIPK3 suppresses systemic spread of Listeria through both MLKL-dependent and -independent pathways. We have added a discussion on this point (page 7, 8).
Comment:
2. How does MLKL limit Listeria without triggering cell death? Clues to mechanism here are provided by the NBB140 experiments shown in Fig 4, wherein the authors find that even unoligomerized MLKL can control Listeria. Given that oligomerization is unnecessary, does full-length MLKL also prevent Listeria growth in this setting? This is an important experiment, because if the full-length unphosphorylated protein can dampen bacterial growth, then the role of RIPK3 in this process becomes complicated. In other words, why phosphorylate MLKL? (Conventionally, phosphorylation of MLKL is thought of as a requisite for release of the NBB domain and membrane targeting.) If full-length (unoligomerized) MLKL does not inhibit Listeria, but NBB140 (unoligomerized) MLKL does, then it would suggest that phosphorylation of MLKL by RIPK3 is needed to release the NBB domain, but that subsequent oligomirization of MLKL is unnecessary for targeting Listeria. Additional controls here would be to show that dimerized RIPK3 (using the same 2xFv system) also limits Listeria, but cannot do so when MLKL is absent (CRISPR) or RIPK3 activity is suppressed (RIPK3 inhibitor).
Response:
We agree that defining the processes through which RIPK3 targets MLKL for disruption of Listeria is important, as it appears to be different from the well-studied necroptosis. In order to define how RIPK3-MLKL suppresses Listeria growth, we have determined; (1) whether RIPK3 catalytic activity is required for the Listeria suppression; and (2) whether oligomerization of MLKL occurs during Listeria invasion. We found that a RIPK3 kinase inhibitor GSK'872 significantly increased Listeria burden in RIPK3-expressing but not in RIPK3-deficient HeLa cells (new Figure 2E) . This indicates that MLKL phosphorylation by RIPK3 is essential for controlling intracellular Listeria growth. However, Listeria-induced activation of MLKL did not lead to its oligomerization (new Figure 3A) . In the canonical TNF, Smac mimetic and Q-VD-OPh (TSQ)-induced necroptosis, RIPK3 phosphorylation of MLKL is implicated in two separate processes, i.e. releasing the NBB domain to allowing translocation of MLKL to plasma membranes; and MLKL oligomerization. Thus, our new results suggest that phosphorylation of MLKL by RIPK3 releases the NBB domain and promotes MLKL to target bacterial membrane without inducing oligomerization, which is sufficient for MLKL to inhibit Listeria growth. Molecular Cell 61(4):589-601 
Comment:

How does active (i.e., phosphorylated) MLKL in Listeria infected cells not trigger cell death, while similar amounts of active MLKL in TSQ-treated cells induce necroptosis? In a stepwise manner, the authors should evaluate compare MLKL status in Listeria versus TSQ-treated cells for (1) MLKL oligomerization (denuaturing gel), (2) MLKL plasma membrane trafficking (immunofluorescence using antibodies to MLKL and pMLKL, or following a Venus-or similarly tagged version of MLKL as shown by Quarato et al in
Response:
As discussed in the above-stated response, we have found that Listeria-induced activation of MLKL did not cause its oligomerization (new Figure 3A) . Furthermore, we did not observe localization of MLKL to the host plasma membrane during Listeria infection (new supplementary Figure. S5A) . We have also determined that intracellular Listeria does not inhibit NBB 140 -2xFV dimerization-induced cell death (new supplementary Figure S4C and D) . These newly obtained results support the idea that Listeria-infection-activated MLKL cannot target the host plasma membrane due to its inability of oligomerization, while oligomerized MLKL targets the plasma membrane leading to necroptosis.
Comment:
Also, is live Listeria required in the cytosol to trigger pMLKL? (Use of an LLO-mutant will help here.)
Response:
We have found that infection of LLO-deficient Listeria (strain B2G6) did not activate the RIPK3-MLKL pathway (please see the results shown bellow). However, since the LLO mutant strain did not efficiently replicate in the cytosol, we found that intracellular burden of LLO mutant Listeria is much less than that of wild type at 24 h post-infection. This suggests that the ability of efficient intracellular replication might be required for MLKL activation to reach a certain level of intracellular Listeria; however, this did not determine whether the presence of live bacteria in the cytosol is needed for MLKL activation. Accordingly, we have decided not to include this result in the manuscript.
Comment:
4. Listeria is a Gram-positive bacterium; its lipid membrane is therefore encased in a cell wall. How do the authors propose MLKL achieves access to the Listeria inner membrane? Can the authors extend their findings to Gram-negative bacteria, such as Salmonella sp. and E.coli? And is lipid binding by MLKL even important for its anti-Listeria activity (Quarato et al describe a mutant of MLKL without lipid binding capacity that will be useful here.) Of note, Gasdermin D is also effective against Gram-positive bacteria.
Response: Peptidoglycan layer that composes the cell wall of Gram-positive bacteria is a dynamic, net-like structure, which is known to be accessible to molecules up to 57 kDa (P.A. Lambert 2002, PMID:
Flag-tagged RIPK3 expressing HeLa cells were infected with wild type (Strain 2858, WT) and LLO deficient mutant (Strain B2G6, LLO-) Listeria (MOI of 100). Protein extracts at 6h and 24h post infection (PI) were analyzed by immunoblotting.
Response:
The same concern is raised by Reviewer 1, and we agree with both reviewers. We have added results showing Mlkl-deficient mice are susceptible to Listeria colonization in the liver compared with littermate control mice (new Figure 1F) .
Comment:
In the remaining figures, the authors rely largely on HeLa cells reconstituted with exogenous RIPK3 to explore how RIPK3 might influence Listeria infection. They show that infection of HeLa cultures causes RIPK3-dependent MLKL phosphorylation and that this suppresses bacterial replication. However, unlike when Listeria infects macrophages and triggers RIPK3-dependent necroptosis (Gonzalez-Juarbe et al 2015 PLoS Pathog. 11:e1005337) , the infected HeLa cells don't die. The key issue is whether this is also true of intestinal epithelial cells (IECs) or it's a peculiarity of HeLa cells. For example, if IECs in the orally infected mice are not dying, then the authors should have no trouble detecting autophosphorylated RIPK3 in WT intestine by IHC (see Webster et al 2018 Methods Mol. Biol. 1857 . Presumably infected vs uninfected mice would also exhibit equivalent TUNEL staining of IECs.
